Thu-21-09-2017, 20:24 PM
(Thu-21-09-2017, 19:11 PM)Caroline Wrote:(Thu-21-09-2017, 16:41 PM)Fred Wrote:(Thu-21-09-2017, 16:16 PM)JohnB Wrote: Is there still no formal word on its effecacy in treating PsA Fred? Or is it targeting the wrong IL to help with PsA
The study for psoriatic arthritis is still going on, they usually get psoriasis done first and then go for psoriatic arthritis. It targets interleukin 23 whereas Cosentyx and Taltz target interleukin 17.
It remains to be seen if 23 is the right target or not, but it made sense for them to go for it as Stelara their other Bio aims at 12 and 23.
I'm sure they will go for psoriatic arthritis as Cosentyx is knocking Stelara off the top shelf so to speak and they will need something to cut their losses.
That won’t work. Il-17 is "the" psoriatic arthritis interleukin.
That is my thought to, but I think they are still playing around to find one that works for both.
I need a cross between Cosentyx and Stelara.